Adaptimmune Therapeutics PLC Cash Flow Statement
ADAPY|9 years of annual SEC 10-K data (FY2016-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
Adaptimmune Therapeutics PLC used $73M in operating cash flow and negative free cash flow of $74M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$70.8M | -$113.9M | -$165.5M | -$158.1M | -$130.1M | -$137.2M | -$95.5M | -$70.1M | -$71.6M |
| Operating Cash Flow | -$73.2M | -$140.9M | -$141.8M | $10.7M | -$53.6M | -$112.5M | -$104.4M | -$54.3M | -$48.2M |
| Capital Expenditures | $886.0K | $4.7M | $29.5M | $8.6M | $2.3M | $1.6M | $3.9M | $24.6M | $11.5M |
| Free Cash Flow | -$74.1M | -$145.6M | -$171.3M | $2.2M | -$55.9M | -$114.1M | -$108.3M | -$79.0M | -$59.7M |
| FCF Margin | -41.6% | -241.5% | -630.9% | 35.0% | -1413.1% | -10169.3% | -182.0% | -208.7% | -420.3% |